SCHEMBL655644

SCHEMBL655644

COCOc1cc(O)c(C=O)c(OCOC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.58
BACE1 P56817 6/20 0.41
TRIM24 O15164 1/20 0.37
TYR P14679 1/20 0.37
TRIM33 Q9UPN9 1/20 0.37
HDAC8 Q9BY41 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
LMNA P02545 1/20 0.35
IGF1R P08069 1/20 0.35
SRC P12931 1/20 0.35
AXL P30530 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10088413 0.92 ERN1 (0.71) ERN1BACE1TRIM24TYRTRIM33
SCHEMBL7894101 0.90 ERN1 (0.51) ERN1BACE1TRIM24TYRTRIM33
SCHEMBL30401888 0.88 ERN1 (0.41) ERN1BACE1HDAC8HDAC3HDAC4
SCHEMBL10088517 0.84 ERN1 (0.46) ERN1BACE1TRIM24TYRTRIM33
SCHEMBL2025457 0.83 ERN1 (0.38) ERN1BACE1HDAC8HDAC3HDAC4
SCHEMBL2323186 0.83 ERN1 (0.45) ERN1BACE1TRIM24TYRTRIM33
SCHEMBL31336006 0.81 HDAC8 (0.36) ERN1BACE1HDAC8HDAC3HDAC4
SCHEMBL22633207 0.81 PRKDC (0.42) ERN1BACE1HDAC8HDAC3HDAC4
SCHEMBL11153165 0.80 ERN1 (0.57) ERN1LMNAALDH1A1USP2CYP3A4
SCHEMBL10922927 0.79 BACE1 (0.52) ERN1BACE1LMNAIGF1RAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240293392-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2024-09-05 US disclosed
EP-4373819-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2024-05-29 EP disclosed
CN-117693507-A Inhibitor compounds 奈奥芬莱有限公司 2024-03-12 CN disclosed
WO-2023002165-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2023-01-26 WO disclosed
WO-2023002165-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2023-01-26 WO disclosed
US-20190322637-A1 METHOD FOR PREPARING HISPIDULIN AND ITS DERIVATIVES TAIPEI MEDICAL UNIVERSITY (TW) 2019-10-24 US disclosed
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
EP-2421833-B1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2015-01-14 EP disclosed
EP-2421833-B1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2015-01-14 EP disclosed
EP-2421833-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-02-29 EP disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed
WO-2010121963-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P ERN1 1873/4885BACE1 2271/4885TRIM24 1665/4885
US-20240293392-A1 INHIBITOR COMPOUNDS MSH2, PMS2, MSH6 ERN1 3307/4885BACE1 2502/4885TRIM24 1000/4885
US-20190322637-A1 METHOD FOR PREPARING HISPIDULIN AND ITS DERIVATIVES HPD, HAAO, HMBS ERN1 4572/4885BACE1 3007/4885TRIM24 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.